Filtered By:
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 2120 results found since Jan 2013.
Applying the COM-B behaviour model to understand factors which impact school immunisation nurses' attitudes towards designing and delivering a HPV educational intervention in post-primary schools for 15-17 year old students in Northern Ireland, UK
CONCLUSION: IMNs feel that they are the most appropriate professionals to design/deliver HPV education for 15-17 year old students. National policy change, based on collaboration between the Public Health Agency and Education Authority, is a key factor in facilitating IMNs to implement this school-based HPV education intervention.PMID:37543445 | DOI:10.1016/j.vaccine.2023.07.066
Source: Vaccine - August 5, 2023 Category: Allergy & Immunology Authors: Terri Flood Marian McLaughlin Ciara M Hughes Iseult M Wilson Source Type: research
Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
CONCLUSIONS: The highest dose level is safe, immunogenic and associated with clinical responses to HPV16-induced lesions. However, as the majority of HGAIN is caused by the other HPV types, further studies should aim at pan-HPV vaccination to prevent or treat HGAIN.PMID:37540563 | DOI:10.1158/1078-0432.CCR-22-3361
Source: Clinical Cancer Research - August 4, 2023 Category: Cancer & Oncology Authors: Karien C M Gosens Sjoerd H van der Burg Marij J P Welters Sanne Boekestijn Nikki M Loof Wim G V Quint Carel J M van Noesel Allard C van der Wal Olivier Richel Wilhelmus J T A Krebber Cornelis J M Melief Henry J C de Vries Jan M Prins Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Prevention and control of HPV and HPV-related cancers in France: the evolving landscape and the way forward - a meeting report
This report covers some critical findings, key challenges, and future steps to improve the status of HPV prevention and control measures in the country.PMID:37537651 | DOI:10.1186/s12919-023-00271-0
Source: Cancer Control - August 3, 2023 Category: Cancer & Oncology Authors: Dur-E-Nayab Waheed Catherine Weil Olivier Didier Riethmuller Eduardo L Franco Jean Luc Pr étet Marc Baay Nubia Munoz Alex Vorsters Source Type: research
Natural and synthetic drugs and formulations for intravaginal HPV clearance
CONCLUSIONS: This article may serve as a valuable resource of information for managing and preventing precancerous carcinogenic HPV infections. Research could be directed toward developing candidate drugs to make evidence-based decisions about advancing them to clinical trials and, eventually, to the market for potential use in the prevention and control of cervical cancer, which is almost always preventable or even curable if detected early.PMID:37535995 | DOI:10.1016/j.jiph.2023.06.016
Source: Cancer Control - August 3, 2023 Category: Cancer & Oncology Authors: Nizar A Khamjan Saba Beigh Abdullah Algaissi Kanu Megha Mohtashim Lohani Majid Darraj Nader Kamli Faisal Madkhali Sajad Ahmad Dar Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Racial, Ethnic, and Gender Differences in the Timing of Initiating the HPV Vaccine in the United States: the Case of Southeast Asian Americans
J Racial Ethn Health Disparities. 2023 Aug 2. doi: 10.1007/s40615-023-01689-0. Online ahead of print.ABSTRACTDespite the availability of the human papillomavirus (HPV) vaccine, non-Latinx (NL) Southeast Asian Americans have the highest incidence of HPV-associated cervical cancer in the US. Little is known about NL-Southeast Asian Americans' HPV vaccination coverage due to being categorized under the "Asian American" monolith. Therefore, this study uses restricted data from the 2011-2018 National Health and Nutrition Examination Survey (NHANES) to disaggregate NL-Southeast Asian Americans and compare this population's age-s...
Source: Cancer Control - August 2, 2023 Category: Cancer & Oncology Authors: Kim-Phuong Truong-Vu Source Type: research
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
Cancers (Basel). 2023 Jul 20;15(14):3692. doi: 10.3390/cancers15143692.ABSTRACTThere is a significant body of research examining the role of human papillomavirus (HPV) in the pathogenesis of cervical cancer, with a particular emphasis on the oncogenic proteins E5, E6, and E7. What is less well explored, however, is the relationship between cervical cancer and herpes simplex virus (HSV). To date, studies examining the role of HSV in cervical cancer pathogenesis have yielded mixed results. While several experiments have determined that HPV/HSV-2 coinfection results in a higher risk of developing cervical cancer, others have ...
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Daniel G Sausen Oren Shechter Elisa S Gallo Harel Dahari Ronen Borenstein Source Type: research
The Clinical Utility of Circulating HPV DNA Biomarker in Oropharyngeal, Cervical, Anal, and Skin HPV-Related Cancers: A Review
Pathogens. 2023 Jul 5;12(7):908. doi: 10.3390/pathogens12070908.ABSTRACTHuman papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated H...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Ioana Maria Andrioaie Ionut Luchian Costin D ămian Giorgio Nichitean Elena Porumb Andrese Theodor Florin Pantilimonescu Bogdan Trandab ăț Liviu Jany Prisacariu Dana Gabriela Budal ă Daniela Cristina Dimitriu Luminita Smaranda Iancu Ramona Gabriela Urs Source Type: research
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
Cancers (Basel). 2023 Jul 20;15(14):3692. doi: 10.3390/cancers15143692.ABSTRACTThere is a significant body of research examining the role of human papillomavirus (HPV) in the pathogenesis of cervical cancer, with a particular emphasis on the oncogenic proteins E5, E6, and E7. What is less well explored, however, is the relationship between cervical cancer and herpes simplex virus (HSV). To date, studies examining the role of HSV in cervical cancer pathogenesis have yielded mixed results. While several experiments have determined that HPV/HSV-2 coinfection results in a higher risk of developing cervical cancer, others have ...
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Daniel G Sausen Oren Shechter Elisa S Gallo Harel Dahari Ronen Borenstein Source Type: research
Frequency of health care provider recommendations for HPV vaccination: a survey in three large cities in China
DISCUSSION: The frequency of HCPs' recommendations for HPV vaccination in China was much lower than that in many developed countries. To enhance the recommendation frequency, medical institutions should help HCPs gain more knowledge of HPV and master communication skills. At the same time, the government should take measures to enhance the accessibility of HPV vaccines. The media should help to alleviate people's concerns and encourage them to face up sexual health.PMID:37497028 | PMC:PMC10366465 | DOI:10.3389/fpubh.2023.1203610
Source: Cancer Control - July 27, 2023 Category: Cancer & Oncology Authors: Yimeng Mao Yuchen Zhao Lingyun Zhang Jie Li Abu S Abdullah Pinpin Zheng Fan Wang Source Type: research
Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties
This study found that net returns from HPV vaccine cost reimbursements are lowest for family physicians ($0.34/dose) and highest for pediatricians ($5.08/dose). Furthermore, a $1 increment in return was associated with an increase in HPV vaccine doses administered (highest for family physicians; 0.08% per dollar). Reimbursement for HPV vaccine costs by private payers is adequate; however, return margins are small for non-pediatric specialties.PMID:37487718 | DOI:10.1370/afm.2990
Source: Annals of Family Medicine - July 24, 2023 Category: Primary Care Authors: Yenan Zhu Yueh-Yun Lin Ruosha Li Cara He David R Lairson Ashish A Deshmukh Kalyani Sonawane Source Type: research
